Antiglycation Potential of Launaea Taraxacifolia on Pentosidine- and Vesperlysine-Like Advanced Glycation End Products (AGEs)

Why It Matters

The extract offers a plant‑based, multitarget alternative to synthetic AGE inhibitors, addressing safety and cost barriers in diabetes care. Its demonstrated antiglycation, antioxidant, and anti‑inflammatory actions could translate into more effective strategies for preventing diabetic complications.

Key Takeaways

• Launaea taraxacifolia leaf extract contains phenolics, saponins, flavonoids.
• Total phenolics measured at 7.27 mg GAE per 100 mg extract.
• Extract inhibited vesperlysine‑like and pentosidine‑like AGE formation.
• Antioxidant activity confirmed via DPPH radical scavenging assay.
• Anti‑inflammatory effect shown by reduced protein denaturation.

Pulse Analysis

Advanced glycation end‑products (AGEs) are a major driver of the so‑called metabolic memory that fuels oxidative stress, chronic inflammation, and the vascular complications of diabetes. Conventional pharmacologic AGE inhibitors such as aminoguanidine have struggled with safety concerns and limited efficacy, prompting a surge of interest in plant‑derived multitarget agents. West African traditional medicine has long employed Launaea taraxacifolia, commonly called African lettuce, for its nutritional and hypoglycaemic properties. Scientific validation of its antiglycation capacity could open a new, low‑cost therapeutic niche.

The recent investigation used a 70 % ethanol leaf extract of L. taraxacifolia and confirmed a rich phytochemical matrix of phenolics, flavonoids, and saponins, with total phenolic content of 7.27 mg gallic‑acid equivalents per 100 mg and flavonoids at 11.03 mg quercetin equivalents per 100 mg. In vitro assays demonstrated robust DPPH radical scavenging and inhibition of protein denaturation, indicating antioxidant and anti‑inflammatory activity. Most notably, the extract curtailed the fluorescence of vesperlysine‑like and pentosidine‑like AGEs in a BSA model, albeit with slightly lower potency than the reference drug aminoguanidine.

These findings position Launaea taraxacifolia as a promising natural regulator of glycoxidative pathways, offering a multitarget approach that aligns with current diabetes‑care strategies focused on inflammation and oxidative damage. Commercialization could appeal to nutraceutical manufacturers seeking evidence‑based botanicals, while further pre‑clinical and clinical trials will be essential to confirm bioavailability, dosing, and safety. If validated, the extract may reduce reliance on synthetic AGE inhibitors and contribute to more affordable, culturally resonant interventions for diabetic populations worldwide.